june
world
health
organ
declar
infect
swine
origin
influenza
viru
reach
pandem
proport
case
record
countri
outbreak
strain
nation
resourc
capac
document
canada
australia
chile
argentina
elsewher
throughout
histori
pandem
influenza
pose
recurr
threat
human
popul
season
influenza
respons
death
per
year
unit
state
capac
influenza
viru
mutat
spread
anim
human
result
intermitt
pandem
pandem
largest
recent
histori
caus
million
death
worldwid
smaller
pandem
associ
mortal
spike
effect
mild
popul
level
expert
believ
pandem
certainli
occur
uncertain
sever
year
ago
avian
influenza
viru
threaten
vector
next
pandem
highli
virul
transmit
infect
chicken
human
absenc
humantohuman
transmiss
result
small
number
case
worldwid
earli
novel
strain
influenza
swine
origin
influenza
infect
emerg
swine
rapidli
spread
human
origin
mexico
strain
prove
highli
infecti
spread
persontoperson
contact
predilect
younger
host
earli
epidemiolog
data
suggest
although
highli
infecti
less
virul
anticip
case
fatal
rate
approxim
infect
individu
major
infect
individu
symptom
mild
selflimit
howev
small
percentag
infect
individu
develop
profound
respiratori
failur
requir
extraordinari
mean
oxygen
support
includ
high
frequenc
oscil
hfo
ventil
extracorpor
membran
oxygen
ecmo
care
sever
ill
patient
pandem
result
increas
need
intens
care
unit
icu
resourc
strain
avail
personnel
equip
littl
excess
capac
care
critic
ill
patient
develop
countri
minim
capac
develop
countri
support
care
antivir
agent
especi
neuraminidas
inhibitor
oseltamivir
zanamivir
mainstay
treatment
influenza
efficaci
reduc
viral
load
abat
symptom
ambulatori
patient
effect
outcom
critic
ill
patient
establish
util
treat
sever
pandem
influenza
may
compromis
widespread
use
emerg
viral
resist
limit
suppli
polici
regard
treatment
strategi
cost
avail
especi
develop
countri
human
anim
data
suggest
cours
influenza
may
favor
influenc
certain
agent
classic
consid
treatment
influenza
compar
inexpens
readili
avail
agent
may
provid
independ
benefit
treat
viral
infect
attract
adjuv
treatment
statin
lower
plasma
lipid
level
inhibit
hmg
coa
reductas
enzym
respons
convert
hmg
coa
mevalon
ratelimit
step
cholesterol
biosynthesi
multipl
observ
studi
suggest
statin
may
benefit
patient
varieti
sever
infect
exert
effect
attenu
inflamm
mechan
activ
uncertain
may
involv
abil
restrict
cholesterol
avail
cell
membran
innat
immun
system
cholesterol
key
compon
lipid
raft
membraneassoci
microdomain
support
cell
signal
respons
exogen
inflammatori
stimuli
raft
disrupt
may
attenu
cellular
respons
inflammatori
stimuli
experiment
studi
show
pretreat
statin
attenu
sever
acut
lung
injuri
ali
follow
intestin
ischemiareperfus
inflammatori
respons
intraven
lipopolysaccharid
challeng
human
volunt
combin
statin
caffein
inhibit
viral
replic
attenu
lung
injuri
murin
influenza
model
populationbas
studi
suggest
statin
associ
reduc
inflammatori
morbid
critic
ill
patient
receiv
reduc
mortal
patient
influenza
chronic
obstruct
pulmonari
diseas
copd
patient
review
hospit
patient
laboratori
confirm
influenza
receiv
statin
time
admiss
vanderm
colleagu
found
statin
use
independ
associ
reduc
risk
death
adjust
ci
multivari
logist
regress
model
benefit
statin
appear
best
establish
patient
receiv
prior
onset
infect
cohort
studi
report
conflict
result
abil
statin
attenu
organ
dysfunct
schmidt
colleagu
find
statin
reduc
mortal
critic
ill
patient
multipl
organ
dysfunct
syndrom
kor
et
al
report
statin
use
benefici
resolv
organ
dysfunct
statin
wide
use
welltoler
medic
rosuvastatin
differ
hmg
coa
reductas
inhibitor
parent
compound
metabol
cytochrom
result
exhibit
fewer
drugdrug
interact
serum
concentr
affect
gene
polymorph
advers
event
seen
rosuvastatin
gener
mild
may
includ
muscl
symptom
howev
myopathi
rhabdomyolysi
occur
infrequ
patient
take
mgday
less
hmgcoa
reductas
inhibitor
doserel
increas
liver
transaminas
creatinin
kinas
ck
observ
small
number
patient
take
rosuvastatin
overal
occurr
clinic
signific
transaminas
increas
low
similar
across
rosuvastatin
dose
rang
mgday
mgday
patient
sever
liver
diseas
may
increas
exposur
rosuvastatin
intern
forum
acut
care
trialist
infact
inform
allianc
investigatorl
clinic
trial
network
whose
remit
improv
care
critic
ill
patient
promot
scientif
rigor
clinic
research
base
preliminari
understand
influenza
member
canadian
critic
care
trial
group
ccctg
work
collabor
member
infact
design
collabor
adjuv
treatment
chat
pilot
trial
investig
feasibl
conduct
intern
therapeut
trial
global
pandem
potenti
adjuv
rosuvastatin
addit
standard
treatment
influenc
clinic
outcom
influenza
associ
critic
ill
multin
feasibl
rct
involv
adult
icu
canada
saudi
arabia
mexico
argentina
australianew
zealand
overview
studi
design
provid
figur
see
figur
abil
recruit
desir
patient
popul
pandem
condit
ie
proport
elig
patient
enrol
chat
pilot
trial
adher
medic
administr
regimen
outlin
studi
protocol
abil
collect
requir
primari
secondari
endpoint
plan
full
chat
trial
number
patient
receiv
openlabel
statin
number
consent
withdraw
impact
approv
consent
model
recruit
rate
dedic
research
coordin
screen
patient
elig
daili
basi
icu
particip
site
studi
inclus
criteria
fulfil
exclus
criteria
present
research
coordin
identifi
patient
potenti
studi
particip
attend
physician
intensivist
confirm
elig
particip
chat
pilot
rct
criteria
identifi
potenti
candid
studi
inclus
includ
critic
ill
adult
patient
year
age
admit
adult
icu
reason
suspect
probabl
confirm
novel
swine
origin
influenza
infect
see
addit
file
requir
mechan
ventil
invas
noninvas
receiv
antivir
therapi
medic
dose
intend
durat
hour
attend
physician
intensivist
must
moder
high
index
suspicion
age
year
resuscit
reintub
order
document
chart
anticip
withdraw
life
support
weight
kg
unabl
receiv
unlik
absorb
enter
studi
drug
eg
incomplet
complet
bowel
obstruct
intestin
ischemia
infarct
short
bowel
syndrom
rosuvastatin
specif
exclus
alreadi
receiv
statin
b
allergi
intoler
statin
c
receiv
niacin
fenofibr
cyclosporin
gemfibrozil
proteas
inhibitor
includ
limit
lopinavir
ritonavir
plan
use
oral
contracept
estrogen
therapi
icu
stay
ck
exce
ul
alt
exce
time
upper
limit
normal
uln
sever
chronic
liver
diseas
childpugh
score
see
addit
file
previou
enrol
trial
pregnanc
breast
feed
time
enrol
receipt
hour
antivir
therapi
known
suspect
clinic
signific
myositi
myopathi
record
reason
elig
patient
random
chat
pilot
trial
follow
categori
substitut
decis
maker
sdm
consent
refus
b
physician
refus
consent
c
sdm
avail
provid
consent
waiveddef
consent
permit
sdm
exist
waiveddef
consent
permit
e
coordin
workload
f
coordin
avail
elig
timewindow
g
enrol
compet
trial
h
specif
requir
enhanc
trial
feasibl
given
need
conduct
pragmat
trial
coenrol
prospect
observ
studi
rct
investig
similar
altern
treatment
oper
icu
set
permit
record
site
permit
local
research
ethic
board
reb
preserv
alloc
conceal
particip
random
central
random
list
distribut
studi
method
centr
research
pharmaci
particip
centr
stratifi
variabl
block
random
base
centr
alon
perform
take
consider
differ
patient
characterist
particip
icu
day
one
consid
day
studi
treatment
initi
may
may
day
random
waiver
consent
prefer
option
particip
enrol
given
context
global
pandem
construct
consent
algorithm
direct
consent
process
site
local
reb
approv
waiver
consent
see
addit
file
trial
request
patient
enrol
studi
consent
defer
sdm
patient
whomev
abl
provid
consent
first
possibl
obtain
consent
within
hour
consent
may
obtain
person
telephon
per
local
practic
event
patient
die
provid
consent
request
permiss
reb
includ
data
collect
studi
particip
use
random
list
provid
studi
method
centr
research
pharmacist
assign
critic
ill
adult
daili
enter
administr
rosuvastatin
match
placebo
day
research
pharmaci
staff
awar
assign
treatment
arm
site
investig
research
coordin
clinic
pharmacist
involv
care
patient
studi
personnel
remain
blind
treatment
assign
oral
placebo
nasogastr
administr
ident
appear
colour
consist
match
crush
rosuvastatin
prepar
pharmaci
toronto
canada
suppli
studi
site
aspect
patient
manag
left
clinician
discret
per
pragmat
trial
design
appli
health
research
centr
keenan
research
centr
li
ka
shing
knowledg
institut
st
michael
hospit
toronto
ontario
studi
method
centr
studi
drug
administ
daili
enter
feed
tube
oral
patient
abl
safe
take
oral
medic
type
placement
enter
feed
tube
nasogastr
nasoenter
percutan
endoscop
gastrostomi
orogastr
oroenter
etc
discret
attend
clinic
team
abil
safe
take
oral
medic
determin
patient
primari
care
team
first
studi
drug
dose
rosuvastatin
placebo
administ
within
hour
random
load
dose
mg
unless
subject
asian
chines
korean
japanes
phillipino
vietnames
asianindian
descent
age
year
serum
creatinin
greater
equal
umol
mgdl
see
requir
dose
adjust
thereaft
dose
mg
administ
hr
daili
hour
start
next
calendar
day
studi
day
mainten
dose
patient
asian
descent
year
serum
creatinin
greater
equal
umol
mgdl
dose
adjust
requir
accord
dose
adjust
algorithm
see
requir
dose
adjust
dose
adjust
necessari
patient
renal
impair
receiv
dialysi
dialysi
start
serum
creatinin
remain
elev
dose
adjust
requir
reason
mainten
dose
administ
intend
time
may
administ
subsequ
hour
intend
time
administr
greater
hour
elaps
sinc
last
schedul
dose
patient
receiv
anoth
load
dose
mainten
dose
resum
next
calendar
day
outlin
miss
dose
reason
outlin
medic
discontinu
consid
protocol
violat
load
mg
daili
mainten
mg
dose
reduc
patient
least
one
parent
asian
descent
load
mg
daili
mg
b
whose
age
year
load
mg
daili
mg
c
whose
serum
creatinin
concentr
greater
equal
umol
mgdl
renal
replac
therapi
load
mg
daili
mg
patient
least
one
parent
asian
descent
andor
age
year
serum
creatinin
greater
equal
umol
mgdl
load
mg
daili
mg
intermitt
oral
antacid
administ
closer
hour
administ
rosuvastatin
avoid
influenc
studi
drug
absorpt
given
substanti
potenti
fals
neg
influenza
result
continu
adjuv
treatment
administr
regardless
test
result
posit
neg
day
criterion
cessat
met
patient
liber
mechan
ventil
invas
noninvas
discharg
icu
day
advanc
day
studi
drug
administr
event
patient
remain
icu
observ
eg
possibl
reintub
initi
noninvas
ventil
studi
drug
administr
advanc
day
discharg
studi
drug
administr
stop
one
follow
condit
met
whichev
come
first
day
random
hospit
discharg
includ
transfer
altern
care
facil
death
ck
note
exceed
ul
absenc
altern
diagnosi
patient
determin
clinic
myositi
myopathi
discret
primari
care
team
patient
may
rechalleng
studi
drug
ck
clinic
find
longer
meet
criterion
alanin
aminotransferas
alt
exce
time
uln
absenc
altern
diagnosi
coadministr
follow
niacin
fenofibr
cyclosporin
gemfibrozil
lopinavir
ritonavir
oral
contracept
estrogen
attend
physician
intensivist
sdm
request
stop
treatment
request
data
collect
continu
patient
withdrawn
therapi
prematur
clinician
encourag
continu
studi
medic
despit
neg
test
due
potenti
fals
neg
result
potenti
role
antiinflammatori
agent
rosuvastatin
sever
lung
diseas
decis
regard
continu
discontinu
antivir
treatment
left
discret
attend
physician
intensivist
feasibl
protocol
ventil
gener
clinic
manag
pandem
condit
adjunct
nonantibiot
nonintervent
manag
sepsi
acut
respiratori
distress
syndrom
glycem
control
discret
patient
primari
clinician
key
aspect
clinic
manag
choic
antivir
dose
administr
durat
treatment
ventil
strategi
treatment
inhal
nitric
oxid
hfo
prone
posit
ecmo
addit
antiviralantiinflammatori
treatment
treat
episod
infect
document
either
part
influenza
swine
flu
icu
registri
studi
particip
centr
separ
data
form
centr
particip
registri
antibiot
therapi
may
prescrib
suspect
confirm
concomit
bacteri
infect
discret
attend
physician
pair
deep
nasopharyng
np
swab
either
endotrach
et
aspir
bronchoalveolar
bal
sputum
intub
influenza
polymeras
chain
reaction
pcr
b
viral
cultur
endotrach
aspir
sputum
intub
gram
stain
cultur
sensit
c
repeat
test
pcr
viral
cultur
site
posit
previous
ie
et
bal
np
swab
et
np
swab
posit
send
repeat
et
aspir
specimen
day
weekli
interv
thereaft
first
neg
specimen
previous
posit
site
send
repeat
specimen
site
hour
first
specimen
collect
verifi
adequ
absorpt
rosuvastatin
draw
venou
blood
peak
trough
plasma
rosuvastatin
concentr
total
specimen
day
day
day
prefer
day
trough
peak
specimen
collect
trough
level
specimen
drawn
prior
day
day
dose
peak
concentr
specimen
drawn
hour
dose
studi
drug
administ
maximum
patient
blood
drawn
drug
concentr
analysi
howev
patient
random
rosuvastatin
sampl
analyz
sampl
label
batch
site
shipment
st
michael
hospit
toronto
canada
analysi
studi
unblind
research
staff
assess
particip
daili
advers
effect
durat
treatment
chat
studi
particip
daili
ck
liver
function
aspart
aminotransferas
ast
alt
level
collect
part
studi
protocol
studi
drug
discontinu
hypersensit
suspect
see
criterion
complet
studi
drug
administr
record
number
patient
receiv
full
treatment
reason
inabl
complet
assign
treatment
durat
ie
death
transfer
altern
care
facil
studi
withdraw
etc
studi
data
safeti
monitor
board
dsmb
review
patient
withdrawn
studi
safeti
data
death
patient
follow
death
hospit
discharg
record
vital
statu
patient
day
hospit
discharg
whichev
occur
first
day
patient
remain
ventil
deem
ventil
depend
random
patient
consid
success
extub
remain
posit
pressur
ventil
invas
noninvas
ventil
consecut
hour
patient
reintub
within
hr
follow
extub
follow
achiev
one
aforement
outcom
patient
discharg
icu
requir
readmiss
reiniti
mechan
ventil
invas
noninvas
treat
accord
usual
practic
random
second
occas
studi
proport
elig
patient
enrol
chat
pilot
studi
adher
medic
administr
regimen
outlin
studi
protocol
proport
complet
primari
secondari
endpoint
plan
full
chat
trial
collect
number
patient
receiv
openlabel
statin
number
consent
withdraw
recruit
rate
approv
consent
model
estim
avail
allow
precis
sampl
size
estim
primari
outcom
propos
chat
pilot
rct
propos
undertak
pilot
studi
conveni
sampl
patient
suspect
probabl
confirm
infect
assess
trial
feasibl
collect
chat
specif
data
start
icu
admiss
use
paperbas
version
electron
data
collect
form
develop
influenza
swine
flu
icu
registri
studi
form
document
baselin
characterist
enrol
concurr
influenza
research
studi
comorbid
ill
sever
see
addit
file
vaccin
statu
cointervent
feasibl
outcom
clinic
outcom
plan
definit
trial
primari
proport
patient
success
wean
mechan
ventil
less
day
secondari
impact
rosuvastatin
icu
day
hospit
mortal
icu
free
day
day
addit
data
form
develop
influenza
swine
flu
icu
studi
develop
addit
form
includ
elig
random
form
ii
sever
ill
form
iii
consent
form
iv
drug
administr
form
v
diagnost
test
result
form
vi
laboratori
data
form
vii
drug
level
serum
specimen
collect
form
viii
day
day
outcom
form
ix
comment
end
studi
investig
sign
x
protocol
violat
form
biochemistri
xi
protocol
violat
form
medic
administrationdiscontinu
xii
advers
event
form
xiii
seriou
advers
event
form
random
patient
centr
particip
registri
draft
addit
form
captur
necessari
demograph
treatment
outcom
inform
addit
draft
form
captur
demograph
data
outcom
elig
random
patient
descript
statist
use
summar
data
univari
analys
use
chisquar
test
altern
fisher
exact
test
expect
cell
size
student
ttest
altern
mannwhitney
utest
normal
assumpt
satisfi
binari
continu
outcom
respect
analys
conduct
intentiontotreat
basi
feasibl
pilot
studi
assess
metric
reflect
capac
ultim
recruit
repres
sampl
patient
plan
full
chat
trial
consid
studi
feasibl
recruit
least
commonli
use
threshold
icu
studi
elig
patient
particip
icu
care
review
site
screen
log
addit
expect
less
medic
dose
fail
administ
absenc
meet
one
medic
discontinu
criteria
ii
less
data
form
miss
import
primari
secondari
outcom
data
requir
plan
full
chat
trial
iii
enrol
patient
withdrawn
prematur
due
open
label
use
statin
withdraw
consent
describ
recruit
rate
base
approv
consent
model
sinc
centr
australia
new
zealand
permit
use
atorvastatin
match
placebo
instead
rosuvastatinmatch
placebo
propos
conduct
plan
primari
secondari
analys
use
pool
data
rosuvastatin
plu
atorvastatin
ii
use
rosuvastatin
predominantli
use
statin
chat
trial
data
alon
dsmb
overse
trial
consist
individu
expertis
viral
infecti
diseas
statist
clinic
critic
care
one
intern
dsmb
hold
teleconfer
either
patient
evalu
data
approxim
month
studi
initi
trial
complet
feasibl
data
pilot
studi
analyz
dsmb
end
studi
inform
convey
steer
committe
togeth
dsmb
steer
committe
formul
decis
whether
proceed
full
trial
clinic
outcom
remain
blind
studi
group
assign
view
includ
plan
larger
trial
investig
evalu
chang
laboratori
valu
physic
sign
determin
chang
clinic
import
differ
expect
cours
treatment
critic
ill
patient
requir
mechan
ventil
suspect
probabl
confirm
influenza
clinic
import
unexpect
advers
experi
occur
record
advers
event
case
report
form
character
advers
event
see
addit
file
expect
seriou
unexpect
studi
relat
unanticip
consid
factor
see
addit
file
includ
patient
withdraw
consent
includ
telephon
consent
waiver
consent
see
addit
file
elig
non
random
patient
equit
select
subject
justif
includ
vulner
subject
women
childbear
age
justif
exclud
pregnant
women
trial
oversight
trial
data
safeti
monitor
board
see
addit
file
design
chat
trial
protocol
investig
plan
make
chang
larger
studi
protocol
base
experi
implement
pilot
trial
regardless
publish
find
chat
pilot
trial
either
alon
pool
anoth
trial
evalu
role
statin
similar
popul
recruit
ensu
even
studi
protocol
modifi
import
way
follow
conduct
pilot
trial
plan
larger
trial
never
come
fruition
pilot
trial
data
may
also
combin
data
larger
trial
latter
trial
come
fruition
studi
personnel
includ
data
analyst
remain
blind
treatment
assign
import
modif
made
studi
protocol
follow
pilot
trial
global
concern
aros
threat
influenza
pandem
despit
potenti
virul
ill
littl
actual
known
sever
diseas
develop
treatment
may
confer
benefit
critic
ill
patient
even
less
known
conduct
clinic
research
set
evolv
pandem
sever
infect
primarili
affect
young
often
previous
healthi
individu
earli
report
support
aborigin
popul
canada
australia
obes
individu
women
especi
pregnant
women
appear
predilect
sever
diseas
unlik
pandem
avail
today
antivir
agent
antibiot
secondari
infect
icu
support
care
intervent
hold
promis
major
patient
sever
ill
save
burden
sever
diseas
fall
promin
icu
consequ
opportun
learn
treatment
sever
diseas
conduct
pandem
critic
care
research
rest
within
icu
commun
data
observ
studi
human
intervent
studi
anim
suggest
cours
influenza
may
favor
influenc
rel
inexpens
readili
avail
agent
rosuvastatin
classic
consid
treatment
influenza
agent
attract
adjuv
treatment
amidst
emerg
report
oseltamivir
resist
threaten
drug
suppli
shortag
howev
abil
administ
test
efficaci
adjuv
agent
treatment
sever
infect
remain
establish
chat
pilot
trial
design
evalu
feasibl
implement
random
control
trial
adjuv
rosuvastatin
treat
sever
infect
pandem
aim
evalu
whether
centr
adher
studi
treatment
regimen
collect
requir
primari
secondari
endpoint
subsequ
plan
full
chat
trial
document
patient
receiv
openlabel
statin
consent
withdraw
also
seek
evalu
impact
approv
consent
model
recruit
rate
sever
timehonor
aspect
rct
design
includ
use
central
random
preserv
alloc
conceal
multilevel
studi
blind
use
match
placebo
pose
challeng
us
design
pandem
protocol
contempl
necess
includ
studi
design
featur
care
deliber
decid
includ
central
random
use
list
distribut
studi
method
centr
particip
centr
preserv
multilevel
blind
involv
pharmaci
particip
centr
contract
local
pharmaceut
compani
prepar
crush
drug
match
placebo
absenc
industri
suppli
studi
drug
avail
placebo
recogn
trial
initi
may
delay
recruit
curtail
priori
inperson
sdm
consent
requir
consid
use
altern
consent
model
priori
inperson
sdm
consent
hing
exist
avail
sdm
also
abil
sdm
access
hospit
pandem
strength
propos
pilot
trial
design
includ
use
central
random
alloc
conceal
multi
level
blind
standard
criteria
medic
discontinu
day
follow
ensur
feasibl
pandem
protocol
test
ventil
sedat
manag
clinic
use
antibacteri
agent
merg
studi
data
influenza
registri
captur
data
uniqu
form
centr
particip
registri
howev
document
key
aspect
clinic
manag
conduct
rct
evolv
pandem
pose
uniqu
challeng
encount
form
clinic
research
first
necessari
initi
studi
quickli
normal
time
interv
concept
first
patient
enrol
new
rct
typic
order
two
year
second
scope
durat
pandem
unknown
unpredict
third
mitig
effect
largescal
vaccin
program
chang
infect
result
viru
mutat
unknown
fourth
practic
conduct
clinic
research
pandem
unknown
exampl
research
personnel
may
second
provid
clinic
care
pharmacist
may
face
challeng
dispens
drug
placebo
reb
may
permit
altern
consent
model
may
difficult
obtain
consent
patient
may
lack
decisionmak
capac
famili
may
unwel
unabl
visit
hospit
request
stay
away
pandem
final
face
clinic
imper
treat
grave
ill
previous
well
young
patient
clinician
may
opt
use
open
label
treatment
rather
permit
enrol
blind
rct
believ
import
develop
capac
initi
rct
pandem
condit
test
studi
procedur
prior
implement
larg
scale
rct
propos
conduct
multicentr
pilot
trial
assess
feasibl
clinic
protocol
studi
procedur
chat
collabor
adjuv
treatment
rct
random
control
trial
icu
intens
care
unit
world
health
organ
hfo
high
frequenc
oscil
ecmo
extracorpor
membran
oxygen
ali
acut
lung
injuri
copd
chronic
obstruct
pulmonari
diseas
ck
creatinin
kinas
infact
intern
forum
acut
care
trialist
ccctg
critic
care
trial
group
uln
upper
limit
normal
sdm
substitut
decis
maker
reb
research
ethic
board
alt
alanin
aminotransferas
np
nasopharng
et
endotrach
tube
bal
bronchoalveolar
lavag
pcr
polymeras
chain
reaction
c
cultur
sensit
ast
aspart
aminotransferas
tcp
tricouncil
polici
statement
dsmb
data
safeti
monitor
board
author
declar
compet
interest
author
contribut
concept
design
chat
pilot
trial
draft
revis
manuscript
import
intellectu
content
author
approv
final
version
manuscript
